OBJECTIVES: For the contemporary health care, creation of patient registries is a crucial task; first of all they facilitate, from the evidence-based medicine position, the problem of introduction of new effective drugs (including biological drugs). The purpose of this study was to describe the first experience of creation a breast cancer patient registry in the Russian Federation.  METHODS: As of 24.07.2012, the Registry included 11,960 patients from 16 regions of Russia. The proportion of Moscow residents is 49.9%.  RESULTS: It is found that only in 9.7% of cases included in the Registry breast cancer was detected at stage I. Most commonly the diagnosis was established at the following stages: IIA (27.5%), IIB (17.1%) and IIIA (19.9%). It is worth noting that in the regions the diagnosis of stage I cancer was established more frequently than in Moscow (chi-square=204, p<0.000). Assessment of the distribution of patients in the Registry by expression of estrogen and progesterone receptors (ER/PR) was performed for only 1195 (16.7%) of cases where test results were available. Positive HER-2 status was found in 14.9% of patients in the Registry. In patients with stage I and stage II, a clear prevalence of HER-2 negative cases was found, whereas in patients with stage III and stage IV positive status prevailed. Hormonal anti-progesterone therapy was given to 1345 patients (94.7% of women with overexpression of estrogen and progesterone receptors). 83 patients received treatment with trastuzumab. This is consistent with the total number of HER-2 positive patients (101); the coverage is equal to 82.2% and considered sufficient.  CONCLUSIONS: Analysis of the Registry revealed insufficient use of up-to-date immunoassays, including estrogens and progesterone receptors typing, it also showed that it is early stages of the disease when one can expect better clinical effect from the use of hormone therapy and biological therapy.